Personalized approach to outpatient management of patients taking tamoxifen by gynecologists

Abstract

BACKGROUND: 30% of women with luminal breast cancer receiving adjuvant tamoxifen experience disease recurrence within 15 years. This demonstrates the wide variability in clinical response to tamoxifen. Both nongenetic (age, gender, body mass index, duration of drug use) and genetic factors have been described to influence the high variability of response to tamoxifen. Differences in the genes encoding the enzymes CYP2D6, CYP2C, and CYP3A (CYP2D6*4, CYP3A5*3, CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C19*3) and the ABCB1 gene (C3435T) may also be the main factors of susceptibility to the occurrence of undesirable effects when taking tamoxifen, which in turn may lead to decreased patient adherence to therapy.

AIM: The aim of this study was to create a concept and an algorithm for a personalized approach to outpatient management of patients taking tamoxifen by a gynecologist in connection with the carriage of polymorphisms of cytochrome P450 and drug transporter genes.

MATERIALS AND METHODS: In 2017–2018, the outpatient records of 230 patients with breast cancer were analyzed retrospectively. A single-stage pharmacogenetic study of 120 women with stage I–III luminal breast cancer taking tamoxifen was conducted prospectively for the presence of cytochrome P450 gene polymorphisms using the polymerase chain reaction method and assessing associations with adverse drug reactions, and 54 patients were interviewed after five-year follow-up to assess adherence and satisfaction with medical supervision.

RESULTS: The likelihood of developing endometrial hyperplasia has been shown to increase while taking tamoxifen with increasing average age, body mass index, duration of tamoxifen use, and postmenopause. Significant associations have been identified between the carriage of the CYP2D6, CYP2C9, CYP2C19, CYP3A5, and ABCB1 gene polymorphisms and the development of adverse drug reactions. Predictive models have been developed to determine the risk of adverse drug reactions. All studied adverse drug reactions associated with various genetic polymorphisms predominated in the group of patients who stopped taking tamoxifen due to poor intolerance. Gynecologists regularly observed 57.4% of patients. Moreover, the higher the adherence to therapy was, the higher was the regularity of observation by a gynecologist.

CONCLUSIONS: A plan for outpatient management of patients receiving adjuvant endocrine therapy with tamoxifen by a gynecologist has been developed.

Keywords

endometrial hyperplasia / breast cancer / tamoxifen / pharmacogenetics / cytochrome P450

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi: 10.3322/caac.21590

[2] Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020 // CA Cancer J Clin. 2020. Vol. 70, N. 1. P. 7–30. doi: 10.3322/caac.21590

[3] Huang B, Warner M, Gustafsson JÅ. Estrogen receptors in breast carcinogenesis and endocrine therapy. Mol Cell Endocrinol. 2015;418(Pt 3):240–244. doi: 10.1016/j.mce.2014.11.015

[4] Huang B., Warner M., Gustafsson J.Å. Estrogen receptors in breast carcinogenesis and endocrine therapy // Mol Cell Endocrinol. 2015. Vol. 418, N. 3. P. 240–244. doi: 10.1016/j.mce.2014.11.015

[5] Sanchez-Spitman AB, Swen JJ, Dezentje VO, et al. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen. Expert Rev Clin Pharmacol. 2019;12(6):523–536. doi: 10.1080/17512433.2019.1610390

[6] Sanchez-Spitman A.B., Swen J.J., Dezentje V.O. et al. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen // Expert Rev Clin Pharmacol. 2019. Vol. 12, N. 6. P. 523–536. doi: 10.1080/17512433.2019.1610390

[7] Sanchez-Spitman A, Dezentjé V, Swen J, et al. Tamoxifen pharmacogenetics and metabolism: results from the prospective CYPTAM study. J Clin Oncol. 2019;37(8):636–646. doi: 10.1200/JCO.18.00307

[8] Sanchez-Spitman A, Dezentje V, Swen J., et al. Tamoxifen pharmacogenetics and metabolism: results from the prospective CYPTAM study // J Clin Oncol. 2019. Vol. 37, N. 8. P. 636–646. doi: 10.1200/JCO.18.00307

[9] Binkhorst L, Mathijssen RH, Jager A, et al. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping. Cancer Treat Rev. 2015;41(3):289–299. doi: 10.1016/j.ctrv.2015.01.002

[10] Binkhorst L., Mathijssen R.H., Jager A., et al. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping // Cancer Treat Rev. 2015. Vol. 41, N. 3. P. 289–299. doi: 10.1016/j.ctrv.2015.01.002

[11] Chirgwin JH, Giobbie-Hurder A, Coates AS, et al. Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 trial of Tamoxifen and Letrozole, Alone and in sequence. J Clin Oncol. 2016;34(21):2452–2459. doi: 10.1200/JCO.2015.63.8619

[12] Chirgwin J.H., Giobbie-Hurder A., Coates A.S. Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 trial of Tamoxifen and Letrozole, alone and in sequence // J Clin Oncol. 2016. Vol. 34, N. 21. P. 2452–2459. doi: 10.1200/JCO.2015.63.8619

[13] Lee M, Piao J, Jeon MJ. Risk factors associated with endometrial pathology in premenopausal breast cancer patients treated with Tamoxifen. Yonsei Med J. 2020;61(4):317–322. doi: 10.3349/ymj.2020.61.4.317

[14] Lee M., Piao J., Jeon M. Risk factors associated with endometrial pathology in premenopausal breast cancer patients treated with Tamoxifen // Yonsei Med J. 2020. Vol. 61, N. 4. P. 317–322. doi: 10.3349/ymj.2020.61.4.317

[15] Condorelli R, Vaz-Luis I. Managing side effects in adjuvant endocrine therapy for breast cancer. Expert Rev Anticancer Ther. 2018;18(11):1101–1112. doi: 10.1080/14737140.2018.1520096

[16] Condorelli R., Vaz-Luis I. Managing side effects in adjuvant endocrine therapy for breast cancer // Expert Rev Anticancer Ther. 2018. Vol. 18, N. 11. P. 1101–1112. doi: 10.1080/14737140.2018.1520096

[17] Yang G, Nowsheen S, Aziz K, Georgakilas AG. Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs. Pharmacol Ther. 2013;139(3):392–404. doi: 10.1016/j.pharmthera.2013.05.005

[18] Yang G., Nowsheen S., Aziz K., et al. Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs // Pharmacol Ther. 2013. Vol. 139, N. 3. P. 392–404. doi: 10.1016/j.pharmthera.2013.05.005

[19] Lorizio W, Wu AH, Beattie MS, et al. Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat. 2012;132(3):1107–1118. doi: 10.1007/s10549-011-1893-4

[20] Lorizio W., Wu A.H., Beattie M.S. et al. Clinical and biomarker predictors of side effects from Tamoxifen // Breast Cancer Res Treat. 2012. Vol. 132, N. 3. P. 1107–1118. doi: 10.1007/s10549-011-1893-4

[21] Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28(23):3784–3796. doi: 10.1200/JCO.2009.26.3756

[22] Burstein H.J., Prestrud A.A., Seidenfeld J., et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer // J Clin Oncol. 2010. Vol. 28, N. 23. P. 3784–3796. doi: 10.1200/JCO.2009.26.3756

[23] Schiavon G, Smith IE. Endocrine therapy for advanced/metastatic breast cancer. Hematol Oncol Clin North Am. 2013;27(4):715–736. doi: 10.1016/j.hoc.2013.05.004

[24] Schiavon G., Smith, I.E. Endocrine therapy for advanced/metastatic breast cancer // Hematol Oncol Clin North Am. 2013. Vol. 27, N. 4. P. 715–736. doi: 10.1016/j.hoc.2013.05.004

[25] Golubenko EO, Savelyeva MI, Poddubnaya IV, et al. Clinical factors of the risk of hyperplastic endometry processes on tamoxifen therapy with breast cancer: retrospective population study. Journal of Modern Oncology. 2023;25(1):63–67. EDN: JRIRIB doi: 10.26442/18151434.2023.1.202117

[26] Голубенко Е.О., Савельева М.И., Поддубная И.В., и др. Клинические факторы риска гиперпластических процессов эндометрия на терапии тамоксифеном рака молочной железы. Результаты ретроспективного популяционного исследования // Современная Онкология. 2023. Т. 25, № 1. С. 63–67. EDN: JRIRIB doi: 10.26442/18151434.2023.1.202117

[27] Dignam JJ, Wieand K, Johnson KA, et al. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst. 2003;95(19):1467–1476. doi: 10.1093/jnci/djg060

[28] Dignam J.J., Wieand K., Johnson K.A., et al. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer // J Natl Cancer Inst. 2003. Vol. 95, N. 19. P. 67–76. doi: 10.1093/jnci/djg060

[29] Franzoi MA, Agostinetto E, Perachino M, et al. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol. 2021;22(7):e303–e313. doi: 10.1016/S1470-2045(20)30666-5

[30] Franzoi M. A., Agostinetto E., Perachino M., et al. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer // Lancet. Oncology. 2021. Vol. 22, N. 7. P. 303–313. doi: 10.1016/S1470-2045(20)30666-5

[31] Bergman L, Beelen ML, Gallee MP, et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ ALERT Group. Assessment of liver and endometrial cancer risk following Tamoxifen. Lancet. 2000;356(9233):881–887. doi: 10.1016/s0140-6736(00)02677-5

[32] Bergman L., Beelen M.L., Gallee M.P., et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ ALERT Group. Assessment of liver and endometrial cancer risk following Tamoxifen // Lancet. 2000. Vol. 356. N. 9233. P. 881–887. doi: 10.1016/s0140-6736(00)02677-5

[33] Golubenko EO, Savelyeva MI, Sozaeva ZA. et al. Predictive modeling of adverse events of tamoxifen therapy for breast cancer (results of a cohort study). Pharmacogenetics and Pharmacogenomics. 2022;(1):63–73. EDN: WJVQIJ doi: 10.37489/2588-0527-2022-1-63-73

[34] Голубенко Е.О., Савельева М.И., Созаева Ж.А., и др. Прогностическое моделирование нежелательных лекарственных реакций тамоксифена при раке молочной железы (результаты когортного исследования) // Фармакогенетика и фармакогеномика. 2022. № 1. С. 63–73. EDN: WJVQIJ doi: 10.37489/2588-0527-2022-1-63-73

[35] Golubenko EO, Savelyeva MI, Sozaeva ZhA, et al. Clinical significance of genetic polymorphism of tamoxifen metabolic enzymes and transporters in breast cancer: results of a population-based cohort study. Farmateka. 2022;29(11–12):118–126. EDN: ZZSEDG doi: 10.18565/pharmateca.2022.11-12.118-126

[36] Голубенко Е.О., Савельева М.И., Созаева Ж.А., и др. Клиническое значение генетического полиморфизма ферментов метаболизма и транспортеров тамоксифена при раке молочной железы: результаты популяционного когортного исследования // Фарматека. 2022. Т. 29, № 11–12. C. 118–126. EDN: ZZSEDG doi: 10.18565/pharmateca.2022.11-12.118-126

[37] Golubenko EO, Savelyeva MI, Sozaeva ZA, et al. Predictive modeling of adverse drug reactions to tamoxifen therapy for breast cancer on base of pharmacogenomic testing. Drug Metab Pers Ther. 2023;38(4):339–347. doi: 10.1515/dmpt-2023-0027

[38] Golubenko E.O., Savelyeva M.I., Sozaeva Z.A. et al. Predictive modeling of adverse drug reactions to tamoxifen therapy for breast cancer on base of pharmacogenomic testing // Drug Metab Pers Ther. 2023. Vol. 38, N. 4. P. 339–347. doi: 10.1515/dmpt-2023-0027

[39] Ivashina SV, Babaeva NA, Motskobili TA, et al. Endometrial atrophy or hyperplasia? Patient management tactics against the background of antiestrogen therapy. P.A. Herzen Journal of Oncology. 2022;11(2):13–19. EDN: WOJJAL doi: 10.17116/onkolog20221102113

[40] Ивашина С.В., Бабаева Н.А. Моцкобили Т.А., и др. Атрофия или гиперплазия эндометрия? Тактика ведения пациенток на фоне антиэстрогенной терапии // Онкология. Журнал им. П.А. Герцена. 2022. Т. 11, № 2. С. 13–19. EDN: WOJJAL doi: 10.17116/onkolog20221102113

[41] Goldstein RB, Bree RL, Benson CB, et al. Evaluation of the woman with postmenopausal bleeding: Society of Radiologists in Ultrasound-Sponsored Consensus Conference statement. J Ultrasound Med. 2001;20(10):1025–1036. doi: 10.7863/jum.2001.20.10.1025

[42] Goldstein R.B., Bree R.L., Benson C.B., et al. Evaluation of the woman with postmenopausal bleeding: Society of Radiologists in Ultrasound-Sponsored Consensus Conference statement // J Ultrasound Med. 2001. Vol. 20, N. 10. P. 1025–1036. doi: 10.7863/jum.2001.20.10.1025

[43] Sinawat S, Chiyabutra T. Increased risk of endometrial abnormalities in breast cancer patients taking Tamoxifen: the need for gynaecologic surveillance. Asian Pac J Cancer Prev. 2004;5(2):183-187.

[44] Sinawat S., Chiyabutra T. Increased risk of endometrial abnormalities in breast cancer patients taking tamoxifen: the need for gynaecologic surveillance // Asian Pac J Cancer Prev. 2004. Vol. 5, N. 2. P. 183–187.

[45] Jindal A, Mohi MK, Kaur M, et al. Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy. J Midlife Health. 2015;6(2):59–65. doi: 10.4103/0976-7800.158947

[46] Jindal A., Mohi M.K., Kaur M., et al. Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy // J Midlife Health. 2015. Vol. 6, N. 2. P. 59–65. doi: 10.4103/0976-7800.158947

RIGHTS & PERMISSIONS

Eсо-Vector